About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGEARLY Phase 1

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

NCT04665947•University of California, Davis

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Metastatic Pancreatic CancerLocally Advanced Pancreatic Adenocarcinoma

Interventions

[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.

Locations

1

United States

Locations (1)

University of California Davis

Sacramento, California, United States

Key Dates

Start Date

December 18, 2020

Primary Completion Date

June 1, 2026

Completion Date

June 1, 2026

Last Updated

May 28, 2025

Related Studies

RECRUITINGPhase 3

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

NCT07409272

Pancreatic CancerMetastatic Pancreatic Cancer+1 more

RECRUITINGPhase 2

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

NCT05065801

Metastatic Pancreatic Cancer

RECRUITINGPhase 1/2

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

NCT04605913

Pancreas CancerMetastatic Pancreatic Cancer+2 more

RECRUITINGPhase 3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

NCT06998940

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma+3 more

RECRUITINGPhase 2

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

NCT06662006

Advanced Metastatic Pancreatic Cancer

RECRUITINGPhase 2

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

NCT06381154

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma+4 more

View all related studies

Contacts

Julie L Sutcliffe

CONTACT

916-734-5536 jlsutcliffe@ucdavis.edu

Sponsors

Lead Sponsor

University of California, Davis

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 28, 2025Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions